Extrafoveal choroidal neovascularization secondary to wet age-related macular degeneration treated with intravitreal bevacizumab.
Considering the risk of recurrence of extrafoveal or juxtafoveal lesions after thermal laser treatment and the risk of poor response to photodynamic therapy, it seems reasonable to discuss with the patient the risks and benefits of antiangiogenic therapy. A case of age-related macular degeneration with an extrafoveal choroidal neovascularization treated with a single injection of intravitreal bevacizumab is described. The patient showed both anatomic and visual acuity improvement at 1 month following treatment that persisted even at the 8-month follow-up visit. Further studies are needed to validate the real risk-benefit ratio of intravitreal bevacizumab for extrafoveal exudative lesions versus the current treatments available.
Mones
Jordi M
JM
Instituto de Microcirugía Ocular, Barcelona, Spain.
Lopez
Mauricio A
MA
Prieto
Jorge A
JA
Rodriguez
Juan P
JP
D000368:Aged; D020533:Angiogenesis Inhibitors / Q000627:therapeutic use*; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab; D020256:Choroidal Neovascularization / Q000175:diagnosis / Q000188:drug therapy* / Q000209:etiology; D005260:Female; D005451:Fluorescein Angiography; D005584:Fovea Centralis; D006801:Humans; D007267:Injections; D008268:Macular Degeneration / Q000150:complications*; D041623:Tomography, Optical Coherence; D042461:Vascular Endothelial Growth Factor A / Q000037:antagonists & inhibitors; D014792:Visual Acuity / Q000187:drug effects; D014822:Vitreous Body
D020533:Angiogenesis Inhibitors; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; C467484:VEGFA protein, human; D042461:Vascular Endothelial Growth Factor A; D000068258:Bevacizumab